AZD 1940

Drug Profile

AZD 1940

Alternative Names: AZD1940

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Analgesics
  • Mechanism of Action Cannabinoid receptor CB1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Neuropathic pain; Pain

Most Recent Events

  • 31 Jul 2009 Discontinued - Phase-I for Neuropathic pain in United Kingdom (PO)
  • 31 Jul 2009 Discontinued - Phase-II for Pain in USA (PO)
  • 07 Dec 2007 Phase-I development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top